TY - JOUR T1 - Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 295 LP - 303 VL - 289 IS - 1 AU - Ann-Maree Duncan AU - Gail M. James AU - Frank Anastasopoulos AU - Athena Kladis AU - Todd A. Briscoe AU - Duncan J. Campbell Y1 - 1999/04/01 UR - http://jpet.aspetjournals.org/content/289/1/295.abstract N2 - Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. We administered the NEP inhibitor ecadotril (0, 0.1, 1, 10, and 100 mg/kg/day), either alone or together with the ACE inhibitor perindopril (0.2 mg/kg/day) by 12-hourly gavage from day 2 to 28 after infarction. Ecadotril increased urine cyclic GMP and BK-(1–9) excretion. Perindopril potentiated the effect of ecadotril on urine cyclic GMP excretion. Neither perindopril nor ecadotril reduced cardiac hypertrophy when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. Administration of ecadotril to perindopril-treated rats decreased plasma Ang-(1–7) levels, increased cardiac BK-(1–9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. These data demonstrate interactions between the effects of NEP and ACE inhibition on remodeling of the infarcted heart and on Ang and BK peptide levels. Whereas increased cardiac BK-(1–9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1–7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. The American Society for Pharmacology and Experimental Therapeutics ER -